PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
18059327-7	2008	Treatment of the mice with zileuton or montelukast reduced the spinal cord inflammation and tissue injury, neutrophil infiltration, TNF-alpha, COX-2 and pERK1/2 expression, PGE(2) and LTB(4) production, and apoptosis.	montelukast	39-50	tumor necrosis factor	Mus musculus	132-141	
28178069-5	2017	In the present study, our results showed that treatment with montelukast could protect DA neurons against 6-hydroxydopamine (6-OHDA)-induced neurotoxicity and its administration significantly attenuated the production of neurotoxic cytokines such as tumor necrosis factor-alpha (TNFalpha) and interleukin-1beta (IL-1beta) from activated microglia in the substantia nigra (SN) and striatum following 6-OHDA treatment.	montelukast	61-72	tumor necrosis factor	Mus musculus	250-277	
28178069-5	2017	In the present study, our results showed that treatment with montelukast could protect DA neurons against 6-hydroxydopamine (6-OHDA)-induced neurotoxicity and its administration significantly attenuated the production of neurotoxic cytokines such as tumor necrosis factor-alpha (TNFalpha) and interleukin-1beta (IL-1beta) from activated microglia in the substantia nigra (SN) and striatum following 6-OHDA treatment.	montelukast	61-72	tumor necrosis factor	Mus musculus	279-287	
24456746-5	2014	Blockade of CysLT1R by repeated treatment with montelukast (1 or 2 mg/kg, ig, 4 weeks) reduced Abeta1-42-induced CysLT1R expression and also suppressed Abeta1-42-induced increments of NF-kappaB p65, TNF-alpha, IL-1beta and caspase-3 activation, and Bcl-2 downregulation in the hippocampus and cortex.	montelukast	47-58	tumor necrosis factor	Mus musculus	199-208	
30862773-9	2019	We also found that montelukast treatment reduced pro-inflammatory factors (TNF-alpha, IL-6, and IL-1ss) production, enhanced superoxide dismutase (SOD) activity, and reduced malondialdehyde (MDA) content in the lung tissues of BPD mice.	montelukast	19-30	tumor necrosis factor	Mus musculus	75-84	
16949072-6	2006	Immunohistochemical analysis revealed that mast cells in the inflamed synovium were one of the major cells producing TNF-alpha and that the number of TNF-alpha positive mast cells was significantly reduced by treatment with montelukast.	montelukast	224-235	tumor necrosis factor	Mus musculus	117-126	
16949072-6	2006	Immunohistochemical analysis revealed that mast cells in the inflamed synovium were one of the major cells producing TNF-alpha and that the number of TNF-alpha positive mast cells was significantly reduced by treatment with montelukast.	montelukast	224-235	tumor necrosis factor	Mus musculus	150-159	
16949072-7	2006	Furthermore, TNF-alpha and SCF mRNA levels in the paws of collagen-induced arthritic mice were markedly decreased by montelukast treatment.	montelukast	117-128	tumor necrosis factor	Mus musculus	13-22	
16949072-8	2006	Montelukast may lead to a beneficial therapeutic effect by inhibiting TNF-alpha production by mast cells.	montelukast	0-11	tumor necrosis factor	Mus musculus	70-79	
32109511-0	2020	Montelukast ameliorates Concanavalin A-induced autoimmune hepatitis in mice via inhibiting TNF-alpha/JNK signaling pathway.	montelukast	0-11	tumor necrosis factor	Mus musculus	91-100	
32109511-10	2020	Montelukast significantly reduced JNK level and NFkappaB p65 expression, and inhibited proinflammatory cytokines (TNF-alpha and IL-6) as well as oxidative stress (MDA, NO, and GSH).	montelukast	0-11	tumor necrosis factor	Mus musculus	114-123